Quoin pharmaceuticals extends exclusive distribution agreement with er-kim for its lead asset, qrx003, for netherton syndrome

Ashburn, va., march 01, 2022 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, quoin pharmaceuticals, inc., has extended its exclusive distribution agreement with er-kim, a partner for biotech companies in central and eastern europe (“cce”), for qrx003, the company's investigational treatment for netherton syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.
QNRX Ratings Summary
QNRX Quant Ranking